Your browser doesn't support javascript.
loading
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.
Ray, Kausik K; Nicholls, Stephen J; Li, Na; Louie, Michael J; Brennan, Danielle; Lincoff, A Michael; Nissen, Steven E.
Affiliation
  • Ray KK; Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK. Electronic address: k.ray@imperial.ac.uk.
  • Nicholls SJ; Victorian Heart Institute, Monash University, Melbourne, VIC, Australia.
  • Li N; Esperion Therapeutics, Ann Arbor, MI, USA.
  • Louie MJ; Esperion Therapeutics, Ann Arbor, MI, USA.
  • Brennan D; Cleveland Clinic, Cleveland, OH, USA.
  • Lincoff AM; Cleveland Clinic, Cleveland, OH, USA.
  • Nissen SE; Cleveland Clinic, Cleveland, OH, USA.
Lancet Diabetes Endocrinol ; 12(1): 19-28, 2024 Jan.
Article in En | MEDLINE | ID: mdl-38061370
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prediabetic State / Cardiovascular Diseases / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Diabetes Mellitus Limits: Humans Language: En Journal: Lancet Diabetes Endocrinol Year: 2024 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prediabetic State / Cardiovascular Diseases / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Diabetes Mellitus Limits: Humans Language: En Journal: Lancet Diabetes Endocrinol Year: 2024 Document type: Article Country of publication: